Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Interesting !

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Feb 18, 2021 8:05pm

291 Views

Post# 32605726

RE:RE:Interesting !

I contacted URO TODAY and, as I suspected, our trial had been mis-categorized. They took immediate action upon receiving my email, relocating our trial so it shows up in the NMIBC search results. If you now search for NMIBC clinical trials TLD-1433 will show up on the second page of results - 4th from the top. If a NMIBC patient is searching for a clinical trial to be a part of it's important they at least know of our existence.

https://www.urotoday.com/clinical-trials/search/update.html?tags=14640&start=20

ScienceFirst wrote:
We're not in there:

The Latest Research on Bladder Cancer - UroToday

We're not in there:

Clinical Trials in Urology - UroToday

By chance, we now have US sites.

__________________________________

Oden6570 - (2/18/2021 5:57:17 AM)
Interesting !
ASCO GU 2021: Optimal Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer in the Non-cystectomy Candidate - Intravesical